Sihuan And Other Leading Chinese Drug Firms Could Get Boost From Current Meeting Of National People's Congress In Beijing
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Sihuan Pharmaceutical Holdings Group, based on the tropical Chinese island of Hainan, could see a sharp upward trajectory in earnings over the next three years as it continues to expand its product portfolio through acquisitions fueled by proceeds raised during its initial public offering and a government push to consolidate the Chinese pharmaceutical industry